Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

G Caleb Alexander; Thomas J Moore; Eric P Brass

doi:10.1016/j.jacc.2024.03.409

Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

J Am Coll Cardiol. 2024 May 14;83(19):1883-1885. doi: 10.1016/j.jacc.2024.03.409.

Authors

G Caleb Alexander¹, Thomas J Moore², Eric P Brass³

Affiliations

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Electronic address: galexan9@jhmi.edu.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
³ David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.

PMID: 38719368
DOI: 10.1016/j.jacc.2024.03.409

No abstract available

Keywords: attention deficit disorder with hyperactivity; central nervous system stimulants; prescribing indicators; prescribing quality; quality of care.

Publication types

Letter
Research Support, Non-U.S. Gov't
Editorial

MeSH terms

Adult
Attention Deficit Disorder with Hyperactivity* / drug therapy
Cardiovascular Diseases* / chemically induced
Central Nervous System Stimulants* / adverse effects
Female
Heart Disease Risk Factors
Humans
Male

Substances

Central Nervous System Stimulants